SG&A at other companies
Segments
By segment
See fullOther financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.
The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about BridgeBio Pharma's sg&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BridgeBio Pharma's SG&A?
- BridgeBio Pharma (BBIO) reported SG&A of $163.9M in Q1 2026.
- How has BridgeBio Pharma's SG&A changed year-over-year?
- BridgeBio Pharma's SG&A increased by 54.1% year-over-year, from $106.37M to $163.9M.
- What is the long-term trend for BridgeBio Pharma's SG&A?
- Over 4 years (2021 to 2025), BridgeBio Pharma's SG&A has grown at a 28.9% compound annual growth rate (CAGR), from $192.21M to $531.23M.
- What does SG&A mean?
- The overhead costs of running the business, including marketing, administration, and corporate support.
- How do you interpret SG&A?
- A decrease relative to revenue suggests improved operational leverage, while an increase may indicate scaling for commercial launches or rising administrative overhead.
- How does SG&A compare across companies?
- Typically benchmarked against peers to determine if administrative overhead is bloated relative to the company's size.